We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Henderson Mrly. | HML | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.085 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.085 | 0.085 |
| Top Posts |
|---|
Posted at 30/6/2012 11:39 by mmelody Disgraceful - even after its demise HML continues a sorry history of utter corruption |
Posted at 27/4/2012 12:34 by thefruits It appears that Ian Pardoe, formerly HML man... has died.Condolences to his family |
Posted at 05/3/2011 15:07 by bi1l Yes, just recently pranchalee, his final comment was along the lines of still in the process of investigating whether there are any actions that may be taken by them which may lead to further recoveries for the benefit of the administration. They dont give much away though but maybe someone told them about the KHV vaccine that ( without us ) should still be ongoing and had or still presumably has considerable value. Unless of course those at HML just made it all up which wouldnt surprise me now. |
Posted at 26/9/2010 09:41 by pwhite73 thefordprefectHow new are you to HML? I was posting on this board at the time of the Cutanae announcement. In March 2006 HML announced they had signed a deal with an 'un-named dermatological pharmaceutical company' but for some unknown reason they would not reveal the name. I remember people ringing up the company and speculating on names like Johnson and Johnson, Pfizer, Eli Lilly and Merck. It was not until September 2006 six months later did HML reveal it was an unknown company called Cutanea. Sceptics like myself pined at the time if this really was a cure for a form of herpes would HML be signing any deals with a nonentity like Cutanea. In the Sept 06 announcement HML talked of royalties of $6.5 million and $115 million after ten years if marketing went to plan. Of course it was all a scam to raise equity. There was no real commercial deal with Cutanea and both parties knew they could never sell such an outdated product in the US. Cutanea were a small US company who were formed that same year 2006. They wanted to give the early impression they were signing international deals and the same applied to HML. Anyway for those of you who think Cutanea, AP and IP have run off with your millions here are the facts. 1. For the third quarter ending 30 June 2010 the auditor J.H. Cohn LLP expressed his doubt that Cutanea can continue as a going concern. 2. As a result of the auditor's report Cutanea filed for a public listing in September 2010 to fund their lead drug omiganan and provide vital working capital. 3. Debts to 30 June 2010 stood at US$20.1 million. 4. There are NO revenues coming in from any of their three candidate drugs inclusive of ICVT. |
Posted at 25/9/2010 23:14 by pwhite73 HML had a failed business model. The products may have worked but nobody wanted them because there were probably better products on the market or HML were simply asking too much.But the real money HML sought was not from deals but from private investors like yourselves buying their ever discounted shares in the hope one day they would strike a genuine multi-million dollar deal. But that is what the AIM game is all about 'tricking investors'. With credit markets dried up and savage cutbacks in research and development spending HML has reached the end of the line. I'm not quite sure why you guys have set up a private BB or what is it you are trying to achieve. The administrators appointed would be specialists in this area. If they thought they could flog any of the IPs for £1 million do you really think they would be selling them back to AP and IP for a paltry £105K. HML is gone and so should be all of you. |
Posted at 17/9/2010 17:26 by jack1236 Care of wuggy, from another siteIn case anyone is interested, the administration formally made it into the London Gazette yesterday It appears, contrary to the RNS of 27th August, that indeed Madison Animal Health hasn't gone into administration. Apparently at that date it was a "wholly owned subsidiary" of HML. As HML is still listed (even though suspended) can I suggest that the Administrator releases an urgent RNS to clarify the situation, as this seems to be of fundamental interest to shareholders in HML? The AIM rules remain in place whether suspended, or in administration, or not.... More from Wuggy Just to reiterate, the 27th August (date of suspension) RNS said: "Pursuant to the procedures in part 2 of The Insolvency Rules, 1986, a notice of intention to appoint an administrator by the Directors of the Company, was filed this afternoon in court. This notice covers Henderson Morley plc, as well as its wholly owned subsidiaries Henderson Morley Research and Development Ltd, and Madison Animal Health Ltd." According to Companies House, as at 30.4.09 Madison was dormant. Then on 4th August 2010 it registered a mortgage/charge at Companies House. Also according to CH, Madison isn't a subsidiary of HML at all - instead it's jointly owned by Knight and Pardoe, and as far as I can see has never been a subsidiary of HML. Madison is also based at HML's address. Or to put it another way.... "W T F is going on????" |
Posted at 01/9/2010 12:05 by kntinshiningarmour Fact is they are under no obligation to disclose why which "deal" did not work and for what reason BUT PRIMARY REASON is this co thought they could get other parties TO DO THE WORK FOR THEM. They did not supervise the "deals", they outsourced control of the technology development and thought partners would do all the work without them lifting a finger. They applied very limited funds themselves to tech development but raised substantial amounts THAT WENT INTO DIRECTORS POCKETS. Their strategy was a lot like a woman who thinks that Mr Perfect will arrive one day and sweep them off their feet without them having to do nought. Well Mr Perfect never arrived. There was never a Plan B. Do you remember when they were Bid Target for a year yet never got an approach nor did anybody buy any part of HML cos no VALUE there. 2008 was a game changer for AIM - but punters did not realise this and nor did a lot of AIM companies. It became clear the funds were not there for companies like HML with pathetic track records, hemmoraging money. After 2008 the FSA clamped down on small brokers selling stocks like HML to clients, it was no longer possible for HML to rely on endless placings. In response to 2008 HML carried on spending money same as usual - they were advised to cut costs as other outfits were doing, but they did not cut costs they insisted on living hand to mouth as usual. This outfit never upped its game and came to the end of the road. |
Posted at 27/8/2010 14:42 by thefruits OK GUYS UPDATEJust had a very insightful conversation with Neil Baldwin. He's agreed that I can post a short summary but here's the position. This morning HML asked AIM to suspend trading in HML shares. The filing to the courts is a legal measure which effectively takes HML into chapter 11 and protects HML from demands from its creditors. HML will file the papers and then its up to the court to decide how long HML have to secure a route of financing. In the meantime, HML are still around, still working on securing funding and Brewin as the NOMAD still have an obligation to stay on the case and AIM rules still apply No guarantee that funding can be achieved in the meantime but this gives a bit of restbite, perhaps only a week or so but sometime for various discussions with various parties either to come to fruition or not. If not then administrators will be appointed Seems that most 3rd party funding options required HML to sign a deal with KMS before they put further equity into the company. Either that or security against the assets. Deemed more favourable (for everyone vs alternatives) to take option of AK & IP to try to take security. NB doesn't believe having worked with AK & IP that they have sought to deliberately defraud the shareholders. Mike - thanks for the heads up. Neil seemed like a honest bloke and I thanked him for his info and his permission to share what I've posted above tf |
Posted at 18/8/2010 06:23 by thefruits I'm struggling to see where we're going here. Lets assume that hml and kms sign the deal and hml get say $500k of cash upfront. Well that will last approx 6 months. Then we'll be looking for another placing unless HML get SPAH to sign the khv deal with an upfront payment.Hence I'm struggling to see what we will have achieved if we sell ICVT for so little. WE've spent 18 months trying to sell it, burning through £1.5m of cash in the process. In the meantime we will have not progressed the KHV deal, or apparently received any grants, no orphan drug approval, no apparent new patents. It just feels like we've lost the last 2 years and spent alot of time and money just to deliver a poor cash injection that will last pitifully short period of time. Ok I could be underestimating how much cost this will save from an operational basis as I have no idea how much ICVT cost HML to administer on an annual basis. Were I so burdened with such useful info I doubt I'd be so confused over hML's strategy Its worth recalling what this deal is supposed to deliver... from HML's mouth The headline points in the LOI are: � Commencement of a 9 week legal and other due diligence period expiring 14 May 2010 � Subject to the above, a license agreement will provide for a payment of up to US$5 million based on certain milestones � This includes an initial US$1.3 million minimum payable on the commencement date of the licence � KMS will assume all costs for patent protection from date of licence � Double digit percentage royalties payable on commercialisation On top of this.. On completion of the transaction, which is conditional on satisfactory due diligence, KMS has agreed to pay Henderson Morley an additional payment of not less than $250,000 in exchange for consultancy services or other specialized work as directed by KMS, and agreed to by Henderson Morley, to help accelerate the time to markets for the products. So what does this mean... Well in my opinion, unless hml deliver at least the amounts signified above then all i can see is further disappointment and share dilution (probably via a consolidation). Thing is, the tone of the recent rns suggested that hml were having issues with closing commercial terms which to me smacks of suggesting we aren't going to even get the meagre returns noted above. This is really all too depressing. Hopefully should give some of us an opportunity to make a move to the exit though with our tails not so firmly between our legs. I feel even good news will be met with a flood of those making moves to the exit. I'll be amongst them unless HML really delivers a stellar deal. I can't see how else we're going avoid further damaging dilution. all imho from a hot and sweaty office somewhere in the far east during a lunch break. gl all, tf |
Posted at 11/8/2010 19:58 by tonyhicken VectorVest Stock Analysis of Henderson Morley Plc as of 10/08/2010 Summary Analysis HML.L is overvalued compared to its Price of 0.11GBX per share, has below average safety, and is currently rated a Sell. Graphs Henderson Morley Plc Drug (Biomedical\\Genetic Detailed Analysis Company Information Business: Henderson Morley Plc, (HML.L) Henderson Morley Plc, a biotechnology company, develops anti-viral drugs and vaccines, and biological products for the pharmaceutical industry primarily in the United Kingdom. The company's pipeline of products include clinical and pre-clinical candidates for various diseases comprising skin warts; verrucae, such as warts on the feet and toes; herpes simplex infections of the mouth, genitalia, and eyes; adenovirus infection of the eyes; and orphan diseases, such as recurrent respiratory papillomatosis. Its product portfolio for animal health includes treatments for feline herpes in cats; vaccine under development for KHV; immunotherapies for canine cancers in dogs; and adjuvants for fish vaccines. The company also develops various vaccine programs targeted at viruses, such as herpes simplex, cytomegalovirus, and epstein barr virus. In addition, it is developing laboratory reagents using marker viruses, vaccine adjuvants, and in-vitro reagents. The company was founded in 1996 and is headquartered in Birmingham, the United Kingdom. Capital Appreciation Value: Value is a measure of a stock's current worth. HML.L has a current Value of 0.03GBX per share. Therefore, it is overvalued compared to its Price of 0.11GBX per share. Value is computed from forecasted earnings per share, forecasted earnings growth, profitability, interest, and inflation rates. Value increases when earnings, earnings growth rate and profitability increase, and when interest and inflation rates decrease. VectorVest advocates the purchase of undervalued stocks. At some point in time, a stock's Price and Value always will converge. RV (Relative Value): RV is an indicator of long-term price appreciation potential. HML.L has an RV of 0.29, which is very poor on a scale of 0.00 to 2.00. This indicator is far superior to a simple comparison of Price and Value because it is computed from an analysis of projected price appreciation three years out, AAA Corporate Bond Rates, and risk. RV solves the riddle of whether it is preferable to buy High growth, High P/E stocks, or Low growth, Low P/E stocks. VectorVest favors the purchase of stocks with RV ratings above 1.00. RS (Relative Safety): RS is an indicator of risk. HML.L has an RS rating of 0.53, which is poor on a scale of 0.00 to 2.00. RS is computed from an analysis of the consistency and predictability of a company's financial performance, debt to equity ratio, sales volume, business longevity, price volatility and other factors. A stock with an RS rating greater than 1.00 is safer and more predictable than the average stock in the VectorVest database. VectorVest favors the purchase of stocks of companies with consistent, predictable financial performance. RT (Relative Timing): RT is a fast, smart, accurate indicator of a stock's price trend. HML.L has a Relative Timing rating of 0.40, which is very poor on a scale of 0.00 to 2.00. RT is computed from an analysis of the direction, magnitude, and dynamics of a stock's price movements over one day, one week, one quarter and one year time periods. Once a stock's price has established a strong trend, it is expected to continue in that trend for the short-term. If a trend dissipates, RT will gravitate toward 1.00. RT will explode from bottoms, dive from tops, and reflect changes in price momentum. VectorVest favors the purchase of stocks with RT ratings above 1.00. VST (VST-Vector): VST is the master indicator for ranking every stock in the VectorVest database. HML.L has a VST rating of 0.42, which is very poor on a scale of 0.00 to 2.00. VST is computed from the square root of a weighted sum of the squares of RV, RS, and RT. Stocks with the highest VST ratings have the best combinations of Value, Safety and Timing. These are the stocks to own for above average, long-term capital appreciation. VectorVest advocates the purchase of safe, undervalued stocks rising in price. Recommendation (REC): VectorVest gives a Buy, Sell, Hold recommendation on every stock, every day. HML.L has a Sell recommendation. REC reflects the cumulative effect of all the VectorVest parameters working together. These parameters are designed to help investors buy safe, undervalued stocks rising in price. They also help investors avoid or sell risky, overvalued stocks falling in price. VectorVest recommends that investors buy high VST-Vector, Buy-rated stocks in rising markets. Stop (Stop-Price): Stop is an indicator of when to sell a long position or cover a short position. HML.L has a Stop of 0.13GBX per share. This is 0.02 above HML.L's current closing Price. A stock's Stop is computed from a 13 week moving average of its closing prices, and is fine-tuned according to the stock's fundamentals. High RV, high RS stocks have lower Stops, and low RV, low RS stocks have higher Stops. In the VectorVest system, a stock gets a 'B' or 'H' recommendation if its Price is above its Stop and an 'S' recommendation if its Price is below its Stop. GRT (Earnings Growth Rate): GRT reflects a company's one to three year forecasted earnings growth rate in percent per year. HML.L has a forecasted Earnings Growth Rate of -6.00%, which VectorVest considers to be very poor. GRT is computed from historical, current and forecasted earnings data. It is updated each week for every stock in the VectorVest database. GRT often foretells a stock's future price trend. If a stock's GRT trend is upward, the stock's price will likely rise. If GRT is trending downward, the stock's Price will probably fall. VectorVest favors the purchase of stocks whose GRT is rising and is greater than the sum of current inflation and interest rates, as shown weekly in our investment climate report. EPS (Earnings per Share): EPS stands for leading 12 months Earnings Per Share. HML.L has a forecasted EPS of 0.00GBX per share. VectorVest determines this forecast from a combination of recent earnings performance and traditional fiscal and/or calendar year earnings forecasts. P/E (Price to Earnings Ratio): P/E is a popular measure of stock valuation which shows the dollars required to buy one dollar of earnings. HML.L has a P/E of -0.62. This ratio may be deemed to be high or low depending upon your frame of reference. The average P/E of all the stocks in the VectorVest database is 28.41. P/E is computed daily using the formula: P/E = Price/EPS. EY (Earnings Yield): EY reflects earnings per share as a percent of Price. EY is related to P/E via the formula, EY = 100 / (P/E), and may be used in place of P/E as a measure of valuation. EY has the advantages that it is always determinate and can reflect negative earnings. HML.L has an EY of -99.00 percent. This is below the current average of 3.52% for all the stocks in the VectorVest database. EY equals 100 x (EPS/Price). GPE (Growth to P/E Ratio): GPE is another popular measure of stock valuation. It compares earnings growth rate to P/E ratio. HML.L has a GPE rating of -9.72. High growth stocks are believed to be able to justify high P/E ratios. A stock is commonly considered to be undervalued when GPE is greater than 1.00 and overvalued when GPE is below 1.00. Unfortunately, this rule of thumb does not take into account the effect of interest rates on P/E ratios. The operative GPE ratio of 1.00 is valid when and only when interest rates equal 10%. With long-term interest rates currently at 6.50%, the operative GPE ratio is 0.42. Therefore, HML.L may be considered to be overvalued. Dividend Information DIV (Dividend): VectorVest reports annual, regular, cash dividends as indicated by the most recent payments. Special distributions, one-time payments, stock dividends, etc., are not generally included in DIV. HML.L does not pay a dividend. DY (Dividend Yield): DY reflects dividend per share as a percent of Price. HML.L does not pay a dividend, so it does not have a Dividend Yield rating. . DY equals 100 x (DIV/Price). It is useful to compare DY with EY. If DY is not significantly lower than EY, the dividend payment may be in jeopardy. DS (Dividend Safety): DS is an indicator of the assurance that regular cash dividends will be declared and paid at current or at higher rates for the foreseeable future. HML.L does not pay a dividend, so it does not have a Dividend Safety rating . Stocks with DS values above 75 typically have RS values well above 1.00 and EY levels that are much higher than DY. DG (Dividend Growth Rate): Dividend Growth is a subtle yet important indicator of a company's financial performance. It also provides some insight into the board's outlook on the company's ability to increase earnings. HML.L does not pay a dividend, so it does not have a Dividend Growth rating . YSG (YSG-Vector): YSG is an indicator which combines DIV, DY and DG into a single value, and allows direct comparison of all dividend-paying stocks in the database. HML.L does not pay a dividend, so it does not have a YSG rating . Stocks with the highest YSG values have the best combinations of Dividend Yield, Safety and Growth. These are the stocks to buy for above average current income and long-term growth. Price-Volume Data Price: HML.L closed on 8/10/2010 at 0.11GBX per share Open: HML.L opened trading at a price of 0.10GBX per share on 8/10/2010. High: HML.L traded at a High price of 0.11GBX per share on 8/10/2010. Low: HML.L traded at a Low price of 0.10GBX per share on 8/10/2010 Close: HML.L closed trading at price 0.11GBX per share on 8/10/2010. (Close is also called Price in the VectorVest system) Range: Range reflects the difference between the High and Low prices for the day. HML.L traded with a range of 0.00GBX per share on 8/10/2010. GBXChange: HML.L closed unchanged from the prior day's closing Price. %PRC: HML.L's Price changed 5.00% from the prior day's closing price. Volume: HML.L traded 2,880,023 shares on 8/10/2010. AvgVol: AvgVol is the 50 day moving average of daily volume as computed by VectorVest. HML.L has an AvgVol of 3,285,900 shares traded per day. %Vol: %Vol reflects the percent change in today's trading volume as compared to the AvgVol. %Vol equals ((Volume - AvgVol) / AvgVol ) * 100. HML.L had a %Vol of -12.35% on 8/10/2010 CI (Comfort Index): CI is an indicator which reflects a stock's ability to resist severe and/or lengthy price declines. HML.L has a CI rating of 0.32, which is very poor on a scale of 0.00 to 2.00. CI is quite different from RS in that it is based solely upon a stock's long-term price history. VectorVest advocates the purchase of high CI stocks. Sales / Market Capitalization Information Sales: HML.L has annual sales of GBX Sales Growth: Sales Growth is the Sales Growth Rate in percent over the last 12 months. HML.L has a Sales Growth of -95.00% per year. This is very poor. Sales Growth is updated each week for every stock. It is often useful to compare Sales Growth to Earnings Growth to gain an insight into a company's operations. Sales Per Share (SPS): HML.L has annual sales of 0.00GBX per share. SPS can be used as a measure of valuation when comparing stocks within an Industry Group. Price to Sales Ratio (P/S): HML.L has a P/S of 35.90. This ratio is also used as a measure of valuation. Here, too, it is useful when comparing stocks within an Industry Group. Shares: HML.L has 1,401,000,000 shares of stock outstanding. Market Capitalization: HML.L has a Market Capitalization of 1,000,000GBX. Market Capitalization is calculated by multiplying price times shares outstanding. Business Sector: HML.L has been assigned to the Drug Business Sector. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors. Industry Group: HML.L has been assigned to the Drug (Biomedical\\Genetic For another stock analysis, please click here. -------------------- Please do not reply to this email. For answers to your questions, please call 1-888-658-7638, or email us at support@vectorvest.c -------------------- Copyright 2008 by VectorVest, Inc. All Rights Reserved. 20472 Chartwell Center Drive, Cornelius NC 28031 For additional information, call 1-888-658-7638, e-mail to support@vectorvest.c or visit our internet site at -------------------- DISCLAIMER: VectorVest is licensed by VectorVest, Inc., and is protected by United States copyright laws and international treaty provisions. The information contained herein is for your exclusive, personal use only. You may print a single copy of any stock analysis for your exclusive use, but it is not to be reproduced for distribution without the expressed written consent of VectorVest, Inc. You should be aware of the risks involved in stock investing, and you use the material contained herein at your own risk. This material is believed to be reliable, but neither VectorVest, Inc., nor any of its suppliers guarantee its accuracy or validity, nor are they responsible for any errors or omissions which may have occurred. The analysis, ratings, and/or recommendations made by VectorVest, and/or any of its suppliers do not provide, imply, or otherwise constitute a guarantee of performance. VectorVest is comprised of reports embodying a unique system of stock analysis. All contents and recommendations are based on data and sources believed to be reliable, but accuracy and completeness cannot be guaranteed. Users should be aware of the risks involved in stock investments. It should not be assumed that future results will be profitable or will equal past performance, real, indicated or implied. VectorVest and/or its principals may purchase or sell any of the securities cited herein. VectorVest and the logostyle, geometric design are, individually and collectively, service marks owned by VectorVest, Inc. VectorVest is published daily by VectorVest, Inc. 20472 Chartwell Center Drive Cornelius, NC 28031 704-895-4095 regards |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
